pMMR Clinical Trials

2 recruiting

pMMR Trials at a Glance

13 actively recruiting trials for pmmr are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Guangzhou, Hangzhou, and Boston. Lead sponsors running pmmr studies include GV20 Therapeutics, First Affiliated Hospital of Zhejiang University, and Dechang Diao.

Browse pmmr trials by phase

Treatments under study

About pMMR Clinical Trials

Looking for clinical trials for pMMR? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new pMMR trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about pMMR clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 3

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Rectal CancerpMMR (Microsatellite Stable Rectal Cancer)
Sun Yat-sen University556 enrolled1 locationNCT07528209
Recruiting
Phase 1

Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients

pMMR/MSS Advanced Colorectal Cancer
West China Hospital9 enrolled2 locationsNCT07510308
Recruiting
Phase 2

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

Colorectal CarcinomaOligometastasespMMR+2 more
First Affiliated Hospital of Zhejiang University51 enrolled1 locationNCT06850103
Recruiting
Phase 2

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Phase 2

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)

pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao86 enrolled1 locationNCT07005570
Recruiting
Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Colorectal Cancer (CRC)pMMR/MSS Adenocarcinoma of the Colon or Rectum
Jun Huang166 enrolled1 locationNCT06791512
Recruiting
Phase 1Phase 2

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
National University Hospital, Singapore16 enrolled2 locationsNCT06513624
Recruiting
Phase 2

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
Shanghai Changzheng Hospital60 enrolled1 locationNCT06930118
Recruiting
Phase 1Phase 2

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 2

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS36 enrolled2 locationsNCT06522919
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302
Recruiting
Phase 2

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT05742425